Methotrexate and rheumatoid arthritis associated interstitial lung disease.
Pierre-Antoine JugeJoyce S LeeJessica LauLeticia Kawano-DouradoJorge Rojas SerranoMarco SebastianiGouri KoduriEric MattesonKarina BonfiglioliMarcio SawamuraRonaldo KairallaLorenzo CavagnaEmanuele Bozzalla CassioneAndreina ManfrediMayra MejiaPedro Rodríguez-HenriquezMontserrat I González-PérezRamcés Falfan-ValenciaIvette Buendia-RoldánGloria Pérez-RubioEsther EbsteinSteven GazalRaphael BorieSébastien OttavianiCaroline KannengiesserBenoît WallaertYurdagul UzunhanHilario NunesDominique ValeyreNathalie Saidenberg-Kermanac'hMarie-Christophe BoissierLidwine Wemeau-StervinouRené-Marc FlipoSylvain Marchand-AdamPascal RichetteYannick AllanoreClaire DromerMarie-Elise TruchetetChristophe RichezThierry SchaeverbekeHuguette LiotéGabriel ThabutKevin D DeaneJoshua J SolomonTracy DoyleJay H RyuIvan RosasV Michael HolersCatherine BoileauMarie-Pierre DebrayRaphael PorcherDavid A SchwartzRobert VassalloBruno CrestaniPhilippe DieudePublished in: The European respiratory journal (2021)
Our results suggest that MTX use is not associated with an increased risk of RA-ILD in patients with RA, and that ILD was detected later in MTX-treated patients.